SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Oruka Reports Week 16 ORKA-001 Trial Results in Psoriasis

Oruka Therapeutics reported 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group in its ongoing EVERLAST-B trial. The company said the results were highly similar to EVERLAST-A.

ORKA

Related stories